China should set aside politics and look at Covid jab imports, world’s largest vaccine maker says

China should set aside politics and look at Covid jab imports, world’s largest vaccine maker says


China needs to set aside political issues on vaccine imports: Serum Institute of India CEO

China needs to move past political considerations and look at importing Covid-19 jabs to end the pandemic globally, according to the chief executive of the world’s latest vaccine manufacturer.

“They need to open themselves up to healthcare and vaccines from the West and set aside any political issues or things that are holding them back,” Adar Poonawalla, CEO of the Serum Institute of India, told CNBC’s Joumanna Bercetche at the World Economic Forum in Davos.

China has experienced a massive spike in Covid-19 cases and fatalities after abruptly ending its zero-Covid policy, which imposed strict lockdowns, mass testing and quarantine on arrival into the country.

China’s full Covid vaccination rate is nearly 87%, according to World Health Organization figures, which show 54% of the population has also been inoculated with a booster jab.

The main Covid vaccines approved for use in China are from Sinovac and Sinopharm. These jabs are less effective against the Omicron variant than are other mRNA vaccines, such as Pfizer and BioNTech’s, several studies have found.

Poonawalla said China’s pandemic reaction of 2020 — which included building hospitals and infrastructure and taking precautions — showed that Beijing could respond rapidly.

He stressed China’s decision not to import vaccines from the U.S., India and elsewhere, which have been “very effective.”

“I think they may have to really seriously look at doing that now, as a booster at least, and take vaccines which have proven, real-world data and efficacy,” he told CNBC. “Otherwise the alternative is that a lot of people in China are going to continue to get infected and we just hope — we wish them the best of luck in trying to manage that crisis and come out of it as soon as possible.”

Here's what lies ahead for China after zero-Covid failed

He added that this also represents a global issue, given the number of people who want to travel to China for business or leisure, as well as the number of Chinese nationals who would be travelling overseas.

“We really need to end the pandemic and infection in every country, because we all need to be safe,” Poonawalla said.

“They’re [China] still making up their minds on which way they want to go and I hope it all ends quickly.”

The Pune-based Serum Institute of India produces more than 1.5 billion vaccine doses annually for various diseases. Poonawalla said that the company would be interested to provide vaccines to China, but that discussions with Beijing officials had been unsuccessful so far.

CNBC has contacted a Chinese government representative for comment.



Source

Medicare Advantage enrollment expected to fall in 2026 as insurers cut back on unprofitable plans
Health

Medicare Advantage enrollment expected to fall in 2026 as insurers cut back on unprofitable plans

Advocates hold signs during a news conference on Medicare Advantage plans in front of the U.S. Capitol on July 25, 2023 in Washington, DC. Alex Wong | Getty Images News | Getty Images Medicare Advantage enrollment is poised to fall for the first time in nearly two decades, according to the Centers for Medicare and […]

Read More
CDC takes down more than a dozen webpages on sexual and gender identity, health equity
Health

CDC takes down more than a dozen webpages on sexual and gender identity, health equity

A sign for the CDC sits outside of their facility at the Centers for Disease Control and Prevention Roybal campus in Atlanta, Georgia, U.S., May 30, 2025. Megan Varner | Reuters More than a dozen pages on the Centers for Disease Control and Prevention website related to sexual and gender identity, health equity, and other […]

Read More
We’re buying the dip in a health and life sciences stock that has gone down enough
Health

We’re buying the dip in a health and life sciences stock that has gone down enough

We’re buying 20 more shares of Danaher at roughly $180 each. Following Thursday’s trade, Jim Cramer’s Charitable Trust will own 470 shares of DHR, increasing its weighting to about 2.31% from about 2.22%. While Danaher has certainly been one of a handful of problematic stocks in the portfolio, we are stepping into the name here, […]

Read More